We hypothesized that mRNA vaccines targeting MMP9 and IGF2BP2 could induce immune infiltration in the tumor microenvironment of patients with immunologically “suppressive” BIS1 and BIS2 tumors. The gene discussed is MMP9; the disease is neoplasm.